Newly-approved plans for office and medical research space point to potential expansion of New Haven’s life science ecosystem at a time when developers in other cities are having trouble filling space in many of the nation’s largest biotech clusters.
In her role since May as the new president and CEO of the state’s biotech trade organization BioCT, Jodie Gillon has recruited 50 new members and added the state’s most prominent life science developer, Carter Winstanley, to the group’s board of directors.
The trade group for Connecticut life science companies is moving into the state’s newest biotech building and adding a prominent developer to its board.
In the shadow of Pfizer Corp.’s Groton research campus, the next generation of life science companies is looking to put Connecticut on the map as an industry growth cluster.
